Verrica Pharmaceuticals (NASDAQ:VRCA), Inc. is a publicly traded clinical‐stage biopharmaceutical company headquartered in West Chester, Pennsylvania. Since its founding in 2016, Verrica has focused exclusively on the development and commercialization of innovative therapies for dermatological conditions with significant unmet medical need. The company’s shares trade on the Nasdaq under the ticker symbol VRCA.
The company’s lead product candidate, VP-102, is a proprietary drug-device combination therapy containing a patent‐protected formulation of cantharidin in a preservative‐free solution with a precision applicator. VP-102 is approved by the U.S. Food and Drug Administration for the treatment of molluscum contagiosum under the brand name ReVeLēV and is currently under supplementary review for the treatment of external genital warts. Verrica is responsible for all aspects of commercialization, including supply chain management, sales and marketing, and patient support programs.
Verrica’s pipeline includes additional development programs leveraging its cantharidin platform as well as exploration of novel compounds for other skin disorders. The company emerged from a series of dermatology research collaborations and completed its initial public offering in December 2019. Since then, Verrica has established strategic partnerships for manufacturing and regulatory support, and has expanded its team across clinical development, medical affairs and commercial operations.
Led by President and Chief Executive Officer Timothy E. Wright, Verrica’s management team combines seasoned professionals from biotech and dermatology-focused pharmaceutical companies. The company’s board of directors includes experts in regulatory affairs, clinical development and corporate governance. While initial launches are focused on the U.S. market, Verrica is actively evaluating opportunities in Europe and other territories to broaden patient access to its branded dermatology therapies.
